AIM: To compare the therapeutic efficacy of fluoroscopy-guided radiofrequency ablation (F-RFA) and ultrasound-guided RFA (US-RFA) in treatment of @entity157 ( @entity157 ). MATERIALS AND METHODS: Between January 2006 and January 2012, 93 @entity1 with small HCCs underwent percutaneous RFA. In 42 @entity1 with 46 HCCs invisible on US, F-RFA was performed following intra-arterial iodised oil injection (group A). The remaining 51 @entity1 with 58 HCCs received US-RFA (group B). Technical effectiveness, complications, @entity5 progression, and @entity1 survival were retrospectively compared between the two groups. RESULTS: Technical effectiveness was achieved in 45 HCCs of group A (97.8%) and 64 HCCs of group B (96.6%; p=0.65). There was no major complication in either group. The 1-, 3-, and 5-year @entity5 progression rates were lower in group A than those of group B with marginal significance (0%, 3.7% and 3.7% in group A, and 13%, 13%, and 13% in group B; p=0.05). The 1-, 3-, and 5-year @entity1 survival rates were 100%, 58.3%, and 51.2% (group A), and 82.4%, 54.9%, and 46.1% (group B; p=0.26). CONCLUSIONS: F-RFA is a feasible and safe treatment for small @entity157 invisible on US. Its therapeutic efficacy was comparable with that of US-RFA.

Fluoroscopy-guided radiofrequency ablation for XXXX : a retrospective comparison with ultrasound-guided ablation.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'small hepatocellular carcinoma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['local tumour']
@entity157 :: (MESH:D006528,Disease) :: ['small hepatocellular carcinoma']
